Cargando…
Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
AIM: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy. PATIENTS & METHODS: In this open-label, single-arm Phase IV study, patients with EGFRm+ (Del19/L858R)...
Autores principales: | Thongprasert, Sumitra, Geater, Sarayut L, Clement, Dana, Abdelaziz, Amr, Reyes-Igama, Jasmin, Jovanovic, Dragana, Alexandru, Aurelia, Schenker, Michael, Sriuranpong, Virote, Serwatowski, Piotr, Suresh, Sheethal, Cseh, Agnieszka, Gaafar, Rabab |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891940/ https://www.ncbi.nlm.nih.gov/pubmed/31807143 http://dx.doi.org/10.2217/lmt-2019-0004 |
Ejemplares similares
-
Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021) -
Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020) -
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
por: Tan, Daniel S.W., et al.
Publicado: (2020) -
Vimentin expression status is a potential biomarker for brain metastasis development in EGFR-mutant NSCLC patients
por: Teocharoen, Rattanawadee, et al.
Publicado: (2021) -
Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)